KMT2A and acute lymphoblastic leukemia: In order to facilitate analysis, RT-MPLA tested T-ALL were assigned into six groups: MLLT10 recombinome (7%, n = 37) (Table 1); KMT2A/SET (grouped together due to their HOXA overexpression) (7%, n = 34); ABL1 (4%, n = 22); ETS (1%, n = 6); other (1%, n = 5) and negative (80%, n = 418).